^
    BIOMARKER:

    RAS wild-type

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 4893; 3265
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    RAS wild-type
    CRC
    anlotinib
    Sensitive: C3 – Early Trials
    BMC Med - 2 weeks - (New C3)
    RAS wild-type
    CRC
    regorafenib
    Sensitive: A1 - Approval
    RAS wild-type
    CRC
    panitumumab
    Sensitive: A1 - Approval
    RAS wild-type
    CRC
    fruquintinib
    Sensitive: B - Late Trials
    RAS wild-type
    CRC
    bevacizumab
    Sensitive: B - Late Trials
    RAS wild-type
    CRC
    ramucirumab
    Sensitive: C2 – Inclusion Criteria
    RAS wild-type
    CRC
    cetuximab
    Sensitive: C2 – Inclusion Criteria
    RAS wild-type
    CRC
    bevacizumab + cetuximab
    Sensitive: C2 – Inclusion Criteria
    RAS wild-type
    CRC
    EGFR inhibitor
    Sensitive: C3 – Early Trials
    RAS wild-type
    CRC
    avelumab
    Sensitive: C3 – Early Trials
    RAS wild-type
    Colon Cancer
    cetuximab
    Resistant: C3 – Early Trials